Wall Street analysts predict that Core Laboratories (NYSE:CLB) will announce earnings of $0.50 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Core Laboratories’ earnings, with estimates ranging from $0.49 to $0.51. Core Laboratories posted earnings per share of $0.58 during the same quarter last year, which would indicate a negative year-over-year growth rate of 13.8%. The company is scheduled to issue its next earnings results on Wednesday, January 30th.

On average, analysts expect that Core Laboratories will report full year earnings of $2.19 per share for the current year, with EPS estimates ranging from $2.10 to $2.30. For the next fiscal year, analysts expect that the company will report earnings of $2.46 per share, with EPS estimates ranging from $2.07 to $3.00. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Core Laboratories.

Core Laboratories (NYSE:CLB) last released its quarterly earnings results on Wednesday, October 24th. The oil and gas company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.63 by $0.01. The firm had revenue of $182.15 million for the quarter, compared to analyst estimates of $178.11 million. Core Laboratories had a return on equity of 68.00% and a net margin of 13.21%. Core Laboratories’s revenue for the quarter was up 11.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.46 EPS.

A number of equities analysts have issued reports on the company. Zacks Investment Research reaffirmed a “sell” rating on shares of Core Laboratories in a research report on Monday, November 12th. ValuEngine raised Core Laboratories from a “hold” rating to a “buy” rating in a research report on Tuesday, September 4th. Cowen set a $82.00 target price on Core Laboratories and gave the company a “hold” rating in a research report on Monday. Stifel Nicolaus assumed coverage on Core Laboratories in a research report on Monday, September 10th. They issued a “hold” rating and a $117.00 target price on the stock. Finally, Morgan Stanley assumed coverage on Core Laboratories in a research report on Tuesday, September 18th. They issued an “equal weight” rating and a $125.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $111.42.

Institutional investors and hedge funds have recently modified their holdings of the stock. Signaturefd LLC grew its stake in Core Laboratories by 403.7% during the 2nd quarter. Signaturefd LLC now owns 811 shares of the oil and gas company’s stock worth $102,000 after buying an additional 650 shares during the last quarter. Cornerstone Wealth Management LLC bought a new position in shares of Core Laboratories in the third quarter worth $122,000. Capital International Inc. CA bought a new position in shares of Core Laboratories in the third quarter worth $156,000. Parallel Advisors LLC grew its stake in shares of Core Laboratories by 73.3% in the third quarter. Parallel Advisors LLC now owns 1,634 shares of the oil and gas company’s stock worth $189,000 after purchasing an additional 691 shares in the last quarter. Finally, WMS Partners LLC bought a new position in shares of Core Laboratories in the second quarter worth $202,000.

Core Laboratories stock opened at $76.20 on Tuesday. The company has a market cap of $3.52 billion, a P/E ratio of 38.10, a P/E/G ratio of 2.51 and a beta of 1.65. The company has a current ratio of 2.31, a quick ratio of 1.85 and a debt-to-equity ratio of 1.83. Core Laboratories has a one year low of $75.19 and a one year high of $130.34.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, November 20th. Investors of record on Friday, October 19th were paid a dividend of $0.55 per share. The ex-dividend date was Thursday, October 18th. This represents a $2.20 dividend on an annualized basis and a yield of 2.89%. Core Laboratories’s payout ratio is currently 110.00%.

About Core Laboratories

Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

Further Reading: How to use beta for portfolio diversification

Get a free copy of the Zacks research report on Core Laboratories (CLB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.